AstraZeneca Highlights Sustained Survival Benefit In Advanced Breast Cancer Study

AstraZeneca Plc (NASDAQ:AZN) on Tuesday reported updated Phase 3 SERENA-6 trial results showing that camizestrant combined with a CDK4/6 inhibitor continued to deliver significant progression-free survival benefits in hormone receptor-positive, HER2-negative advanced breast cancer.